Hypophosphataemia

1. Clinical Overview

Summary

Hypophosphataemia is defined as serum phosphate less than 0.8 mmol/L (2.5 mg/dL), with severe hypophosphataemia occurring at levels less than 0.3 mmol/L (1.0 mg/dL). [1] Phosphate is an essential intracellular anion, critical for ATP synthesis, cell signaling, bone mineralization, and oxygen delivery via 2,3-diphosphoglycerate (2,3-DPG) in erythrocytes. [2] The condition represents a common electrolyte disturbance in hospitalized patients, affecting 2-5% of general admissions and up to 30% of intensive care unit (ICU) patients. [3]

The most clinically significant scenario is refeeding syndrome, where malnourished or starved patients develop acute, life-threatening hypophosphataemia upon carbohydrate refeeding due to rapid intracellular phosphate shift driven by insulin. [4] Other important causes include diabetic ketoacidosis (DKA) treatment, chronic alcoholism, primary hyperparathyroidism, Fanconi syndrome, vitamin D deficiency, and hungry bone syndrome post-parathyroidectomy. [5]

Severe hypophosphataemia causes multi-organ dysfunction through ATP depletion: respiratory failure (diaphragm weakness), cardiac arrhythmias and heart failure, rhabdomyolysis, haemolytic anaemia, encephalopathy, and seizures. [6] Recognition and prevention are paramount, particularly in high-risk groups undergoing nutritional rehabilitation. Treatment involves oral phosphate supplementation for mild cases and intravenous phosphate polyfusor for severe symptomatic hypophosphataemia, with careful monitoring to avoid complications. [7]

Key Facts

• Definition: Serum phosphate less than 0.8 mmol/L (2.5 mg/dL)
• Severe Definition: Serum phosphate less than 0.3 mmol/L (1.0 mg/dL)
• Incidence: 2-5% hospitalized patients; 30% ICU patients [3]
• Critical Scenario: Refeeding syndrome
• Major Consequences: Respiratory failure, arrhythmias, rhabdomyolysis, haemolysis, encephalopathy
• Mechanism: ATP depletion → cellular energy failure
• Treatment Threshold: IV replacement for severe (less than 0.3 mmol/L) or symptomatic cases
• Mortality: Refeeding syndrome carries 10-20% mortality if unrecognized [8]

Clinical Pearls

"Refeeding = Re-PHOSPHATE": When feeding a starved patient, insulin drives phosphate (along with K+ and Mg2+) into cells. Always start feeds slowly (10 kcal/kg/day in high-risk) and supplement phosphate, potassium, and magnesium proactively. [4]

"No Phosphate, No ATP": Phosphate is literally part of adenosine tri-PHOSPHATE. Severe deficiency causes cellular energy failure affecting high-energy tissues first: diaphragm, myocardium, brain.

"Feed Low, Go Slow": NICE CG32 guideline—start refeeding at 10 kcal/kg/day (or 5 kcal/kg/day in very high risk) and give Pabrinex (thiamine) BEFORE feeding to prevent Wernicke's encephalopathy. [9]

"IV Phosphate Needs Monitoring": IV phosphate can precipitate with calcium causing hypocalcaemia and cardiac arrhythmias. Always give with cardiac monitoring and avoid concurrent calcium infusions. [7]

"DKA Treatment Trap": Phosphate drops during DKA treatment as insulin drives it intracellularly. Monitor and replace if less than 0.6 mmol/L, especially if symptomatic. [10]

"Hungry Bones Eat Phosphate": Post-parathyroidectomy or thyroidectomy, bones avidly take up calcium and phosphate, causing severe hypophosphataemia and hypocalcaemia ("hungry bone syndrome"). [11]

---

2. Epidemiology

Incidence and Prevalence

Hypophosphataemia is a common electrolyte abnormality in clinical practice:

• General hospital admissions: 2-5% [3]
• Intensive care unit (ICU): 20-30% [3]
• Alcoholic patients: Up to 50% [12]
• Malnourished/eating disorder patients: 10-20% before refeeding [4]
• Post-surgical (major abdominal/parathyroid surgery): 30-40% [11]
• DKA treatment: 50-80% develop hypophosphataemia during treatment [10]

Demographics

• Age: More common in elderly due to malnutrition, polypharmacy, and chronic disease
• Sex: No significant sex predilection except for conditions with sex bias (e.g., anorexia nervosa—female predominance)
• Geography: Higher in resource-limited settings with malnutrition

At-Risk Groups for Refeeding Syndrome

The NICE CG32 guideline identifies high-risk criteria for refeeding syndrome: [9]

One or more of:

• BMI less than 16 kg/m²
• Unintentional weight loss > 15% in preceding 3-6 months
• Little or no nutritional intake for > 10 days
• Low baseline potassium, phosphate, or magnesium prior to feeding

Or two or more of:

• BMI less than 18.5 kg/m²
• Unintentional weight loss > 10% in preceding 3-6 months
• Little or no nutritional intake for > 5 days
• History of alcohol or drug misuse (including insulin, chemotherapy, diuretics, antacids)

Specific High-Risk Populations:

• Anorexia nervosa and other eating disorders
• Chronic alcoholism
• Oncology patients (chemotherapy-induced anorexia)
• Post-operative patients (prolonged nil-by-mouth)
• Elderly and care home residents with poor nutrition
• Post-bariatric surgery
• Chronic malabsorption (inflammatory bowel disease, coeliac disease)
• Uncontrolled diabetes mellitus (DKA)
• Prolonged fasting or hunger strikes
• Chronic kidney disease on dialysis
• Chronic liver disease

---

3. Aetiology and Pathophysiology

Phosphate Homeostasis

Normal Physiology:

Total body phosphate is approximately 700 g (85% in bone as hydroxyapatite, 14% intracellular, 1% extracellular). [2] Serum phosphate represents less than 0.2% of total body stores, so serum levels may not reflect true total body depletion. Normal serum phosphate is 0.8-1.5 mmol/L (2.5-4.5 mg/dL).

Regulation:

• Intestinal absorption: 60-70% absorbed in jejunum via sodium-phosphate co-transporters [2]
• Renal handling: 85-90% filtered phosphate is reabsorbed in proximal tubule via sodium-phosphate co-transporters (NaPi-IIa, NaPi-IIc) [2]
• Hormonal control:
  • "PTH: Increases urinary phosphate excretion (phosphaturic)"
  • "FGF23: Increases urinary phosphate excretion and decreases 1,25-dihydroxyvitamin D synthesis"
  • "1,25-dihydroxyvitamin D: Increases intestinal phosphate absorption"
  • "Insulin: Drives phosphate intracellularly"

Cellular Functions of Phosphate

1. Energy metabolism: Component of ATP, ADP, creatine phosphate [2]
2. Nucleic acids: DNA and RNA backbone structure
3. Phospholipid membranes: Cellular membrane integrity
4. Protein phosphorylation: Cell signaling cascades
5. Bone mineralization: Hydroxyapatite [Ca₁₀(PO₄)₆(OH)₂]
6. Oxygen delivery: 2,3-DPG production in erythrocytes (right-shifts oxygen-haemoglobin dissociation curve) [6]
7. Glycolysis: Phosphorylation of glucose and intermediates

Mechanisms of Hypophosphataemia

Hypophosphataemia occurs through three main mechanisms:

1. Redistribution (Intracellular Shift)

Refeeding Syndrome: [4]

• Starvation state: Glycogen depleted, body uses fat/protein for energy; total body phosphate depleted but serum phosphate normal (shifts from intracellular to extracellular)
• Carbohydrate refeeding: Insulin release stimulates glycolysis and protein synthesis
• Insulin-driven shift: Phosphate (along with K⁺, Mg²⁺) rapidly moves intracellularly for ATP synthesis
• Serum phosphate crashes: Severe hypophosphataemia develops within 24-72 hours
• Consequences: ATP depletion, multi-organ dysfunction

Other redistributive causes:

• Respiratory alkalosis: pH ↑ → stimulates glycolysis → phosphate consumption [13]
• Hungry bone syndrome: Post-parathyroidectomy; avid bone uptake of calcium and phosphate [11]
• Treatment of DKA: Insulin therapy drives phosphate intracellularly [10]
• Rapid cell proliferation: Acute leukaemia treatment, stem cell engraftment
• Catecholamine surge: Sepsis, burns (β-adrenergic stimulation)

2. Decreased Intestinal Absorption

• Malabsorption syndromes: Coeliac disease, inflammatory bowel disease, short bowel syndrome
• Phosphate binders: Aluminium/magnesium/calcium-containing antacids, sevelamer (used in CKD)
• Vitamin D deficiency: Reduced intestinal phosphate absorption [14]
• Chronic diarrhoea: GI phosphate losses
• Poor dietary intake: Malnutrition, alcoholism, anorexia nervosa

3. Increased Renal Losses

Primary Hyperparathyroidism: [5]

• Elevated PTH → inhibits proximal tubular phosphate reabsorption
• Classic biochemistry: ↑ Ca²⁺, ↓ PO₄³⁻, ↑ PTH

Fanconi Syndrome: [15]

• Generalized proximal tubular dysfunction
• Causes: Cystinosis, Wilson's disease, multiple myeloma (light chains), ifosfamide, tenofovir, heavy metals
• Features: Phosphaturia, glycosuria, aminoaciduria, bicarbonate wasting (type II RTA)

X-linked Hypophosphataemic Rickets (XLH):

• Mutation in PHEX gene → ↑ FGF23 → renal phosphate wasting [14]
• Presents in childhood with rickets, bone pain, short stature

Tumour-Induced Osteomalacia (TIO):

• Mesenchymal tumours secrete FGF23 → renal phosphate wasting
• Presents with bone pain, fractures, muscle weakness [14]

Diuretics:

• Acetazolamide (proximal tubule effect)
• Loop diuretics and thiazides (volume depletion → secondary hyperparathyroidism)

Post-Renal Transplant:

• Persistent hyperparathyroidism (tertiary) post-transplant

Osmotic diuresis:

• Hyperglycaemia (diabetes)
• Mannitol therapy

Pathophysiology of Clinical Manifestations

Respiratory Failure

The diaphragm is a highly metabolically active muscle dependent on ATP for contraction. [6] Severe hypophosphataemia (less than 0.3 mmol/L) causes:

• Diaphragm weakness and contractile dysfunction
• Reduced maximum inspiratory pressure
• Respiratory muscle fatigue
• Difficulty weaning from mechanical ventilation
• Type II respiratory failure

Cardiac Dysfunction

Myocardial contractility depends on ATP for actin-myosin cross-bridge cycling. [6] Effects include:

• Reduced cardiac output and heart failure
• Arrhythmias (ventricular tachycardia, torsades de pointes)
• Prolonged QT interval
• Increased mortality in critically ill patients

Rhabdomyolysis

Skeletal muscle ATP depletion causes: [6]

• Impaired calcium sequestration in sarcoplasmic reticulum
• Uncontrolled muscle contraction and breakdown
• Release of myoglobin, CK, potassium
• Acute kidney injury (myoglobin precipitation in tubules)

Haemolytic Anaemia

Erythrocyte ATP depletion leads to: [6]

• Rigid, spherocytic red cells
• Haemolysis (reduced RBC lifespan)
• Decreased 2,3-DPG → left-shifted oxygen-haemoglobin curve → impaired tissue oxygen delivery

Neurological Dysfunction

• Encephalopathy (confusion, irritability, delirium)
• Seizures (severe cases)
• Peripheral neuropathy (paraesthesias)
• Impaired leukocyte chemotaxis (increased infection risk)

---

4. Clinical Presentation

Symptoms

Symptoms are often non-specific and related to underlying cause. Severity correlates with degree and rapidity of phosphate decline.

Mild Hypophosphataemia (0.6-0.8 mmol/L)

• Often asymptomatic
• May have mild weakness or malaise

Moderate Hypophosphataemia (0.3-0.6 mmol/L)

• Muscle weakness (proximal > distal)
• Fatigue and malaise
• Bone pain (chronic cases)
• Anorexia
• Paraesthesias

Severe Hypophosphataemia (less than 0.3 mmol/L)

• Severe muscle weakness (may be unable to mobilise)
• Respiratory failure (dyspnoea, tachypnoea, inability to wean from ventilator)
• Confusion, irritability, delirium
• Seizures
• Rhabdomyolysis (muscle pain, myoglobinuria—dark urine)
• Haemolysis (pallor, jaundice)
• Cardiac symptoms: Palpitations, chest pain, heart failure

Clinical Features by System

Refeeding Syndrome Presentation

Timeline: Develops within 24-72 hours of starting nutritional support in at-risk patients. [4]

Classic triad:

1. Hypophosphataemia (earliest and most severe)
2. Hypokalaemia
3. Hypomagnesaemia

Clinical features:

• Oedema (fluid retention due to insulin-mediated sodium retention and thiamine deficiency)
• Acute heart failure (high-output cardiac failure)
• Respiratory failure
• Arrhythmias
• Confusion, seizures
• Rhabdomyolysis

Red flag: Rapid deterioration in previously malnourished patient within 2-3 days of starting feeds.

---

5. Clinical Examination

General Inspection

• Cachexia or evidence of malnutrition (muscle wasting, subcutaneous fat loss)
• Confusion or altered mental state
• Signs of chronic liver disease (alcoholism)
• Signs of malignancy (cachexia, lymphadenopathy)
• Eating disorder stigmata: Lanugo hair, Russell's sign (calluses on knuckles from self-induced vomiting)

Vital Signs

• Tachycardia (cardiac dysfunction, arrhythmias)
• Hypotension (cardiomyopathy, fluid shifts in refeeding)
• Tachypnoea (respiratory muscle weakness, compensatory)
• Fever (infection—impaired leukocyte function; or rhabdomyolysis)

Respiratory Examination

• Shallow breathing (diaphragm weakness)
• Use of accessory muscles
• Reduced chest expansion
• Paradoxical abdominal breathing (diaphragm fatigue)
• Signs of respiratory failure: Cyanosis, confusion, inability to speak in full sentences

Cardiovascular Examination

• Arrhythmias (irregular pulse)
• Signs of heart failure: Elevated JVP, third heart sound, pulmonary oedema (crackles), peripheral oedema
• Hypotension

Neuromuscular Examination

• Generalised muscle weakness (test power in proximal and distal muscles)
• Hyporeflexia or areflexia
• Muscle tenderness (rhabdomyolysis)
• Sensory abnormalities (paraesthesias, peripheral neuropathy)
• Confusion or reduced GCS

Musculoskeletal Examination (Chronic Hypophosphataemia)

• Bone tenderness (osteomalacia)
• Skeletal deformities (rickets in children)
• Proximal myopathy (difficulty standing from squatting, climbing stairs)

Examination Findings in Underlying Causes

Exam Detail: ### Examination Viva Scenario

Examiner: "You are asked to see a 28-year-old woman in the medical ward who was admitted 3 days ago with anorexia nervosa for nutritional rehabilitation. She is now confused and short of breath. Please examine the respiratory and neuromuscular systems."

Candidate approach:

General inspection: Cachectic woman, BMI appears less than 16 kg/m², using accessory muscles, appears confused and disorientated.

Vital signs: HR 110 bpm, BP 95/60 mmHg, RR 28/min, SpO₂ 92% on room air, temperature 37.1°C.

Respiratory: Tachypnoeic, shallow breathing, paradoxical abdominal movement (diaphragm weakness), reduced chest expansion bilaterally, clear lung fields on auscultation.

Neuromuscular: Generalised proximal muscle weakness (power 3/5 in shoulder abduction and hip flexion), hyporeflexia, no focal neurology.

Findings: This patient has developed refeeding syndrome 3 days after starting nutritional rehabilitation. The examination findings of respiratory muscle weakness (shallow breathing, paradoxical abdominal movement) and proximal myopathy with hyporeflexia are consistent with severe hypophosphataemia.

Examiner: "What investigations would you request urgently?"

Candidate:

• Urgent blood tests: Serum phosphate, potassium, magnesium, calcium, glucose, renal function, CK (rhabdomyolysis), FBC (haemolysis)
• ABG: Assess for respiratory failure and acid-base status
• ECG: Check for arrhythmias and prolonged QT interval
• CXR: Exclude pulmonary pathology, assess for pulmonary oedema

Examiner: "Phosphate is 0.2 mmol/L. What is your immediate management?"

Candidate:

• Stop or reduce enteral/parenteral feeding to 50% of current rate
• IV phosphate replacement: Phosphate polyfusor (9 mmol in 250 mL 0.9% saline over 6-12 hours), with cardiac monitoring
• Replace potassium and magnesium: IV potassium chloride and magnesium sulphate
• Thiamine: Continue Pabrinex or oral thiamine
• Monitor electrolytes: Recheck phosphate, potassium, magnesium 6-hourly for first 24 hours
• Respiratory support: Consider HDU/ICU admission for close monitoring; may need non-invasive ventilation or intubation if respiratory failure worsens
• Restart feeding cautiously: Once phosphate > 0.5 mmol/L, restart at 5 kcal/kg/day with ongoing electrolyte supplementation

---

6. Differential Diagnosis

Conditions Mimicking Hypophosphataemia Symptoms

Causes of Similar Biochemical Pattern

---

7. Investigations

First-Line Investigations

Arterial Blood Gas (ABG)

• Respiratory alkalosis: Can cause intracellular phosphate shift (pH ↑ → glycolysis ↑)
• Metabolic acidosis: May be present in DKA or renal tubular acidosis (Fanconi syndrome)
• Type II respiratory failure: pO₂ ↓, pCO₂ ↑ (diaphragm weakness)

ECG

• Arrhythmias: Ventricular ectopics, VT, torsades de pointes
• Prolonged QT interval: Increased risk of arrhythmias
• Non-specific ST-T wave changes

Urinalysis

• Glycosuria (normoglycaemic): Suggests Fanconi syndrome
• Proteinuria: Myeloma (light chains causing Fanconi syndrome)
• Myoglobinuria: Dark urine in rhabdomyolysis

Second-Line Investigations (If Cause Unclear)

Calculating Fractional Excretion of Phosphate (FE_PO4)

Used to differentiate renal from non-renal causes:

Formula: FE_PO4 (%) = (Urine PO₄ × Plasma Creatinine) / (Plasma PO₄ × Urine Creatinine) × 100

Interpretation:

• FE_PO4 less than 5%: Appropriate renal conservation → extrarenal cause (e.g., redistribution, GI loss)
• FE_PO4 > 5%: Renal phosphate wasting (e.g., hyperparathyroidism, Fanconi syndrome, XLH)

Imaging

---

8. Management

General Principles

1. Identify and treat underlying cause
2. Prevent refeeding syndrome in high-risk patients
3. Replace phosphate according to severity and symptoms
4. Correct concurrent electrolyte abnormalities (K⁺, Mg²⁺, Ca²⁺)
5. Monitor closely during replacement to avoid complications

---

Prevention of Refeeding Syndrome

NICE CG32 Guideline (2006): [9]

┌──────────────────────────────────────────────────────────┐
│   REFEEDING SYNDROME PREVENTION PROTOCOL                 │
├──────────────────────────────────────────────────────────┤
│                                                          │
│  STEP 1: IDENTIFY HIGH-RISK PATIENTS                     │
│  ────────────────────────────────────                    │
│  One or more of:                                         │
│   • BMI less than 16 kg/m²                                        │
│   • Unintentional weight loss > 15% in 3-6 months        │
│   • Little/no nutritional intake > 10 days               │
│   • Low K⁺, PO₄³⁻, or Mg²⁺ before feeding              │
│                                                          │
│  Or two or more of:                                      │
│   • BMI less than 18.5 kg/m²                                      │
│   • Unintentional weight loss > 10% in 3-6 months        │
│   • Little/no nutritional intake > 5 days                │
│   • History alcohol/drug misuse (insulin, chemo,        │
│     diuretics, antacids)                                 │
│                                                          │
│  STEP 2: BEFORE FEEDING                                  │
│  ────────────────────────                                │
│   • Measure PO₄³⁻, K⁺, Mg²⁺, Ca²⁺, U&E, glucose, FBC   │
│   • Correct deficiencies BEFORE starting feeds:          │
│     - Potassium: IV 40 mmol over 4 hours                │
│     - Magnesium: IV 20 mmol over 12 hours               │
│     - Phosphate: Oral Sandoz Phosphate 2 tabs TDS       │
│   • Give PABRINEX (thiamine 200-300 mg IV) or oral      │
│     thiamine 200-300 mg/day to prevent Wernicke's       │
│                                                          │
│  STEP 3: START FEEDS SLOWLY                              │
│  ────────────────────────────                            │
│   • Very high risk (BMI less than 14, > 15 days no food):         │
│     Start at 5 kcal/kg/day                              │
│   • High risk (NICE criteria):                          │
│     Start at 10 kcal/kg/day (max 500 kcal/day)          │
│   • Increase gradually over 4-7 days to target          │
│   • Provide adequate protein: 1.2-1.5 g/kg/day          │
│                                                          │
│  STEP 4: SUPPLEMENT ELECTROLYTES                         │
│  ────────────────────────────                            │
│   • Phosphate: Oral Sandoz Phosphate 2-4 tabs TDS       │
│   • Potassium: Oral Sando-K 2-4 tabs TDS                │
│   • Magnesium: Oral magnesium glycerophosphate 2-4      │
│     tabs TDS                                             │
│   • Thiamine: 200-300 mg/day for at least 10 days       │
│                                                          │
│  STEP 5: MONITOR CLOSELY                                 │
│  ────────────────────                                    │
│   • Daily (BD in first 3 days): PO₄³⁻, K⁺, Mg²⁺, Ca²⁺  │
│   • Daily: U&E, glucose, FBC                            │
│   • Fluid balance, weight, vital signs                  │
│   • Clinical assessment: oedema, confusion, SOB         │
│   • ECG if arrhythmias or prolonged QT                  │
│   • Consider HDU/ICU for very high-risk patients        │
│                                                          │
└──────────────────────────────────────────────────────────┘

---

Phosphate Replacement

Oral Phosphate Replacement

Indications:

• Mild-moderate asymptomatic hypophosphataemia (0.3-0.8 mmol/L)
• Prevention in at-risk patients

Preparations:

• Phosphate-Sandoz® tablets: Each tablet contains 16.1 mmol phosphate
  • "Dose: 2 tablets three times daily (TDS)"
  • "Side effects: Diarrhoea, nausea, abdominal discomfort"

Monitoring:

• Recheck serum phosphate after 24-48 hours
• Adjust dose based on response

Intravenous Phosphate Replacement

Indications:

• Severe hypophosphataemia (less than 0.3 mmol/L)
• Symptomatic hypophosphataemia (respiratory failure, arrhythmias, rhabdomyolysis, haemolysis, encephalopathy)
• Inability to tolerate oral replacement (severe GI symptoms, nil-by-mouth)

Preparation:

• Phosphate Polyfusor®: 50 mmol phosphate in 500 mL (0.1 mmol/mL)
  • "Also contains: 81 mmol Na⁺, 9.5 mmol K⁺ per 500 mL"

Dosing:

Alternative regimen (weight-based):

• 0.08-0.16 mmol/kg IV over 6-12 hours [7]

Precautions:

• Cardiac monitoring: Risk of arrhythmias
• Check calcium levels: IV phosphate can precipitate with calcium → hypocalcaemia
• Avoid concurrent IV calcium: Do NOT give calcium and phosphate in same IV line (precipitation)
• Recheck phosphate: 6 hours after infusion completion; repeat dose if still less than 0.6 mmol/L
• Avoid rapid infusion: Risk of hypocalcaemia, hypotension, arrhythmias

Complications of IV phosphate:

• Hypocalcaemia (calcium-phosphate precipitation)
• Hyperphosphataemia (over-replacement)
• Hypotension
• Arrhythmias
• Tissue calcification (if co-infused with calcium)
• Hypernatraemia (phosphate polyfusor contains sodium)
• Hyperkalaemia (phosphate polyfusor contains potassium)

---

Concurrent Electrolyte Replacement

Refeeding syndrome typically causes combined deficiencies—replace all:

Potassium

• Target: > 4.0 mmol/L during refeeding
• Oral: Sando-K® 2 tablets TDS (12 mmol K⁺ per tablet)
• IV: 40 mmol KCl in 1 L 0.9% saline over 4 hours (max 10 mmol/hour via peripheral line; higher rates via central line with cardiac monitoring)

Magnesium

• Target: > 0.75 mmol/L
• Oral: Magnesium glycerophosphate 4 mmol tablets, 2 tablets TDS
• IV: 20 mmol MgSO₄ in 100 mL 0.9% saline over 12 hours

Calcium (if hungry bone syndrome or concurrent hypocalcaemia)

• Oral: Calcium carbonate 1.25 g (500 mg elemental calcium) TDS
• IV (symptomatic hypocalcaemia): 10 mL 10% calcium gluconate in 100 mL 0.9% saline over 10 minutes
  • Do NOT give in same line as phosphate

Thiamine (Vitamin B1)

• CRITICAL in refeeding syndrome to prevent Wernicke's encephalopathy
• Pabrinex®: 2 pairs IV TDS for 3 days, then 1 pair daily for 3-5 days
• Oral: Thiamine 200-300 mg daily for at least 10 days

---

Management of Specific Scenarios

Diabetic Ketoacidosis (DKA)

During DKA treatment, insulin drives phosphate intracellularly. [10]

Approach:

• Monitor phosphate: Check at baseline and every 4-6 hours during insulin therapy
• Replace if less than 0.6 mmol/L and symptomatic (weakness, arrhythmias)
• Routine prophylactic replacement NOT recommended (no mortality benefit, risk of hypocalcaemia) [10]
• Use oral replacement if tolerating oral intake

Hungry Bone Syndrome

Post-parathyroidectomy or thyroidectomy (especially if large goitre or severe hyperparathyroidism pre-operatively). [11]

Pathophysiology: Bones avidly take up calcium and phosphate post-operatively → severe, prolonged hypocalcaemia and hypophosphataemia.

Management:

• Monitor: Daily calcium, phosphate, magnesium, PTH post-operatively
• Calcium replacement: Aggressive oral calcium (up to 6 g elemental calcium/day) + alfacalcidol 1-2 mcg daily
• Phosphate replacement: Oral Sandoz Phosphate 2-4 tablets TDS
• Magnesium replacement: Often needed
• Duration: May require weeks to months of supplementation
• Endpoint: Biochemistry normalises, bone avidity decreases

Vitamin D Deficiency and Osteomalacia

Mechanism: Vitamin D deficiency → reduced intestinal phosphate absorption; secondary hyperparathyroidism → renal phosphate wasting. [14]

Management:

• Replace vitamin D:
  • "Colecalciferol loading: 20,000 units weekly for 7 weeks, then maintenance 800-2000 units daily"
  • Aim for 25-OH-D > 50 nmol/L
• Calcium supplementation: 1-1.5 g elemental calcium daily
• Phosphate replacement: Usually not needed once vitamin D repleted (intestinal absorption improves)
• Monitor: Calcium, phosphate, ALP, vitamin D at 3 months

Fanconi Syndrome

Generalized proximal tubular dysfunction → phosphate, bicarbonate, glucose, amino acid wasting. [15]

Management:

• Treat underlying cause (stop offending drug, treat Wilson's disease, treat myeloma)
• Phosphate replacement: High-dose oral phosphate (up to 6-8 tablets/day in divided doses)
• Bicarbonate replacement: Oral sodium bicarbonate for type II RTA (dose titrated to venous bicarbonate > 22 mmol/L)
• Vitamin D: Calcitriol 0.25-0.5 mcg daily (active vitamin D, bypasses renal 1α-hydroxylase deficiency)
• Potassium replacement: If hypokalaemic

X-Linked Hypophosphataemic Rickets (XLH)

Management: [14]

• Phosphate replacement: High-dose oral phosphate (divided doses, typically 5-6 times/day to maintain serum levels)
• Active vitamin D: Calcitriol or alfacalcidol (increases intestinal phosphate absorption)
• Burosumab: Monoclonal antibody against FGF23 (approved for XLH in children and adults; improves phosphate levels and bone outcomes)
• Monitoring: Risk of nephrocalcinosis with phosphate + vitamin D therapy; renal ultrasound surveillance

Tumour-Induced Osteomalacia (TIO)

Management: [14]

• Curative: Surgical resection of FGF23-secreting tumour (if localisable)
• Medical (if tumour not localisable or unresectable): Same as XLH (phosphate + calcitriol)
• Burosumab: Effective medical therapy
• Imaging: Whole-body MRI or FDG-PET/CT to localise occult tumours

---

Monitoring During Treatment

---

9. Complications

Complications of Hypophosphataemia

Complications of Refeeding Syndrome

• Cardiac failure: Fluid overload, thiamine deficiency (wet beriberi)
• Wernicke's encephalopathy: Thiamine deficiency (confusion, ophthalmoplegia, ataxia)
• Death: 10-20% mortality if unrecognized [8]
• Prolonged ICU stay: Respiratory failure requiring ventilation
• Arrhythmias: Sudden cardiac death

Complications of Treatment

---

10. Prognosis and Outcomes

With Appropriate Treatment

• Mild-moderate hypophosphataemia: Excellent prognosis with oral replacement
• Severe hypophosphataemia: Good prognosis if recognized and treated promptly
• Refeeding syndrome: Excellent outcomes with proper prevention protocols (slow feeding, electrolyte supplementation, monitoring)

Without Treatment

• Severe hypophosphataemia (less than 0.3 mmol/L): High morbidity and mortality
• Refeeding syndrome (unrecognized): 10-20% mortality [8]
• Chronic hypophosphataemia: Progressive osteomalacia, pathological fractures, disability

Prognostic Factors

Specific Condition Outcomes

Refeeding Syndrome:

• With NICE guideline adherence: less than 1% mortality [9]
• Without recognition: 10-20% mortality [8]
• Key: Slow feeding (5-10 kcal/kg/day) + electrolyte monitoring + supplementation

DKA-related hypophosphataemia:

• Usually self-limiting with insulin cessation
• Prophylactic replacement NOT associated with improved outcomes [10]
• Monitor and replace if symptomatic or less than 0.6 mmol/L

Hungry bone syndrome:

• May require months of calcium and phosphate supplementation
• Eventually resolves as bone turnover normalizes
• Risk of persistent hypoparathyroidism post-operatively (separate issue)

Chronic renal phosphate wasting (XLH, Fanconi, TIO):

• Lifelong treatment often required
• Surgical cure possible in TIO if tumour resected
• Burosumab improves quality of life in XLH [14]

---

11. Guidelines and Evidence

Key Guidelines

1. NICE CG32: Nutrition Support for Adults (2006, updated 2017) [9]

   • Defines refeeding syndrome risk criteria
   • Recommends slow feeding (10 kcal/kg/day in high-risk, 5 kcal/kg/day in very high-risk)
   • Electrolyte monitoring and supplementation protocol
   • Thiamine supplementation to prevent Wernicke's encephalopathy

2. ASPEN Guidelines: Refeeding Syndrome (2020) [4]

   • Risk stratification and prevention strategies
   • Emphasis on multidisciplinary nutrition support teams
   • Monitoring protocols for at-risk patients

3. Joint British Diabetes Societies (JBDS): Management of DKA in Adults (2021) [10]

   • Routine phosphate replacement NOT recommended
   • Monitor and replace if less than 0.6 mmol/L and symptomatic
   • No mortality benefit from prophylactic replacement

Landmark Studies

Refeeding Syndrome:

• Mehanna et al., BMJ 2008 [4]: Systematic review defining refeeding syndrome pathophysiology, risk factors, and prevention strategies. Highlighted mortality risk and need for slow feeding protocols.

• Rio et al., Nutrition 2013 [8]: Retrospective study showing 10-20% mortality in unrecognized refeeding syndrome, reduced to less than 1% with prevention protocols.

Hypophosphataemia in Critical Illness:

• Geerse et al., Crit Care Med 2010 [3]: Found 30% incidence of hypophosphataemia in ICU patients; associated with increased duration of mechanical ventilation and ICU stay.

• Zazzo et al., Intensive Care Med 1995 [6]: Demonstrated that severe hypophosphataemia (less than 0.3 mmol/L) causes diaphragm weakness and respiratory failure, impairing ventilator weaning.

DKA Management:

• Wilson et al., Arch Dis Child 2004 [10]: Randomized trial showing no benefit of prophylactic phosphate replacement in DKA treatment (no difference in morbidity/mortality).

Hungry Bone Syndrome:

• Witteveen et al., Eur J Endocrinol 2013 [11]: Defined hungry bone syndrome incidence (up to 50% post-parathyroidectomy for severe hyperparathyroidism) and management strategies.

X-Linked Hypophosphataemic Rickets:

• Carpenter et al., N Engl J Med 2018 [14]: Phase 3 trial showing burosumab (anti-FGF23 antibody) improves phosphate levels, bone outcomes, and quality of life in XLH.

Evidence Summary

---

12. Examination Focus

Viva Questions and Model Answers

Exam Detail: Q1: A 32-year-old woman with anorexia nervosa (BMI 14 kg/m²) is admitted for nutritional rehabilitation. What are the key steps in preventing refeeding syndrome?

Model Answer:

Refeeding syndrome is a life-threatening complication characterized by severe hypophosphataemia, hypokalaemia, and hypomagnesaemia occurring within 24-72 hours of starting nutrition in malnourished patients. This patient meets high-risk criteria (BMI less than 16 kg/m²).

Prevention strategy (NICE CG32):

1. Pre-feeding assessment:

   • Measure baseline phosphate, potassium, magnesium, calcium, U&E, glucose
   • Correct deficiencies BEFORE starting feeds
   • Give Pabrinex (thiamine 200-300 mg IV) to prevent Wernicke's encephalopathy

2. Start feeds slowly:

   • BMI 14 kg/m² = very high risk → start at 5 kcal/kg/day (max 500 kcal/day)
   • Increase gradually over 4-7 days to target

3. Electrolyte supplementation:

   • Phosphate: Oral Sandoz Phosphate 2-4 tablets TDS
   • Potassium: Sando-K 2-4 tablets TDS
   • Magnesium: Magnesium glycerophosphate 2-4 tablets TDS
   • Thiamine: Continue 200-300 mg/day for 10 days

4. Intensive monitoring:

   • Phosphate, potassium, magnesium, calcium: BD for first 3 days, then daily
   • Daily U&E, glucose, FBC
   • Fluid balance, weight, vital signs
   • Clinical assessment for oedema, confusion, dyspnoea

5. HDU/ICU consideration: For very high-risk patients (BMI less than 14, prolonged starvation > 15 days)

---

Q2: A 55-year-old man in ICU develops a phosphate level of 0.2 mmol/L on day 3 of TPN. He is on a ventilator and difficult to wean. What is the pathophysiology and how would you manage this?

Model Answer:

Pathophysiology:

This patient has severe hypophosphataemia (less than 0.3 mmol/L), likely iatrogenic from TPN-induced refeeding syndrome. The mechanism is:

1. TPN contains high glucose → insulin release
2. Insulin drives phosphate (and K⁺, Mg²⁺) intracellularly for glycolysis and ATP synthesis
3. Serum phosphate crashes despite total body depletion
4. ATP depletion affects high-energy tissues: diaphragm, myocardium, brain

Difficulty weaning from ventilator: The diaphragm is highly metabolically active and dependent on ATP for contraction. Hypophosphataemia causes diaphragm weakness, impaired maximum inspiratory pressure, and respiratory muscle fatigue, preventing successful weaning.

Management:

1. IV phosphate replacement:

   • Severe symptomatic hypophosphataemia → phosphate polyfusor 18 mmol (180 mL) in 500 mL 0.9% saline over 12 hours
   • Cardiac monitoring during infusion (risk of arrhythmias)

2. Check and replace concurrent electrolytes:

   • Potassium, magnesium, calcium (often co-depleted in refeeding)

3. Adjust TPN:

   • Ensure TPN contains adequate phosphate (typically 20-40 mmol/day)
   • Reduce carbohydrate load temporarily to slow insulin-driven shift

4. Monitor:

   • Recheck phosphate 6 hours post-infusion
   • Repeat dose if still less than 0.6 mmol/L
   • Monitor calcium (risk of hypocalcaemia with IV phosphate)

5. Avoid complications:

   • Do NOT co-infuse calcium (precipitation)
   • Monitor for hypotension, arrhythmias

Prognosis: Once phosphate corrected, diaphragm function improves and weaning usually successful within 24-48 hours.

---

Q3: What is hungry bone syndrome and how does it present?

Model Answer:

Definition: Hungry bone syndrome is severe, prolonged hypocalcaemia and hypophosphataemia occurring post-parathyroidectomy or thyroidectomy due to avid skeletal uptake of calcium and phosphate by previously suppressed bone.

Pathophysiology:

• Pre-operatively: Severe hyperparathyroidism → high bone turnover (osteoclast-mediated resorption)
• Post-operatively: Removal of parathyroid adenoma → PTH drops → osteoclast activity ceases
• Osteoblasts continue forming new bone → bones "hungry" for calcium and phosphate
• Severe, rapid depletion of serum calcium and phosphate

Risk factors:

• Large parathyroid adenoma
• Severe pre-operative hyperparathyroidism (Ca²⁺ > 3.0 mmol/L, PTH > 200 pg/mL)
• Elevated alkaline phosphatase (high bone turnover)
• Vitamin D deficiency
• Large goitre (thyroidectomy)

Presentation:

• Timing: Within 24-72 hours post-operatively
• Hypocalcaemia symptoms: Perioral paraesthesias, Chvostek's sign, Trousseau's sign, carpopedal spasm, seizures (severe)
• Hypophosphataemia symptoms: Muscle weakness, bone pain
• Biochemistry: ↓ Ca²⁺ (less than 2.0 mmol/L), ↓ PO₄³⁻, ↓ Mg²⁺, suppressed PTH, elevated ALP

Management:

• Aggressive calcium replacement: Oral calcium carbonate up to 6 g elemental calcium/day + alfacalcidol 1-2 mcg daily
• Phosphate replacement: Oral Sandoz Phosphate 2-4 tablets TDS
• Magnesium replacement: Often required
• IV calcium if symptomatic (10 mL 10% calcium gluconate over 10 minutes)
• Duration: May require weeks to months; wean as biochemistry normalizes

Differentiation from hypoparathyroidism: Both cause hypocalcaemia post-parathyroidectomy, but hungry bone syndrome also causes hypophosphataemia (vs. hyperphosphataemia in hypoparathyroidism).

---

Q4: How would you investigate a patient with persistent hypophosphataemia of unclear cause?

Model Answer:

Approach: Determine whether hypophosphataemia is due to redistribution, decreased absorption, or increased renal losses.

First-line investigations:

• Serum phosphate, calcium, PTH, vitamin D (25-OH-D): Assess for hyperparathyroidism or vitamin D deficiency
• U&E: Assess renal function
• Glucose: Exclude DKA or hyperglycaemia
• Magnesium: Often co-depleted
• Urinalysis: Glycosuria (normoglycaemic) suggests Fanconi syndrome

Second-line investigations:

• Fractional excretion of phosphate (FE_PO4):
  • "Formula: (Urine PO₄ × Plasma Creatinine) / (Plasma PO₄ × Urine Creatinine) × 100"
  • less than 5%: Extrarenal cause (redistribution, GI loss)

  • 5%: Renal phosphate wasting

If renal phosphate wasting (FE_PO4 > 5%):

If FGF23 elevated:

• X-linked hypophosphataemic rickets (XLH): Childhood onset, family history, skeletal deformities → genetic testing (PHEX mutation)
• Tumour-induced osteomalacia (TIO): Adult onset, bone pain, fractures → whole-body MRI or FDG-PET/CT to localise occult tumour

If extrarenal cause (FE_PO4 less than 5%):

• Redistribution: Recent feeding (refeeding syndrome), DKA treatment, respiratory alkalosis (ABG)
• GI losses: Coeliac serology, assess for malabsorption, check medication history (antacids, phosphate binders)

---

13. Patient/Layperson Explanation

What is Hypophosphataemia?

Hypophosphataemia means you have low phosphate levels in your blood. Phosphate is an essential mineral that your body uses to make energy (in the form of a molecule called ATP). It's also important for healthy bones, muscles, nerves, and blood cells.

Why Does It Happen?

Low phosphate can happen for several reasons:

1. Refeeding syndrome: This is the most serious cause. It happens when someone who hasn't been eating properly (due to starvation, anorexia, or severe illness) starts eating again. The body suddenly needs a lot of phosphate to process food, and blood phosphate levels drop dangerously low.

2. Diabetes treatment: When people with very high blood sugar (diabetic ketoacidosis) are treated with insulin, phosphate moves into cells, causing blood levels to drop.

3. Alcohol misuse: Heavy alcohol use can lead to malnutrition and low phosphate levels.

4. Kidney problems: Some conditions cause the kidneys to lose too much phosphate in the urine.

5. Vitamin D deficiency: Vitamin D helps your body absorb phosphate from food. If vitamin D is low, phosphate absorption decreases.

6. Certain medications: Some antacids and diuretics (water pills) can lower phosphate levels.

What Are the Symptoms?

Mild low phosphate may not cause symptoms. If phosphate drops very low, you might experience:

• Muscle weakness (especially in the legs and arms)
• Tiredness and feeling unwell
• Difficulty breathing (if the breathing muscles become weak)
• Confusion or memory problems
• Bone pain (if phosphate is low for a long time)
• Irregular heartbeat or heart problems

How Serious Is It?

• Mild cases are usually not serious and can be easily treated.
• Severe cases (phosphate less than 0.3 mmol/L) can be life-threatening, especially if they cause breathing problems, heart rhythm issues, or muscle breakdown.
• Refeeding syndrome is particularly dangerous and can be fatal if not recognized and prevented.

How Is It Diagnosed?

A simple blood test measures your phosphate level. Your doctor may also check other minerals (potassium, magnesium, calcium) and kidney function.

How Is It Treated?

Treatment depends on severity:

1. Mild cases:

   • Phosphate tablets (Phosphate-Sandoz) taken by mouth, usually 2 tablets three times a day
   • May cause some diarrhoea as a side effect

2. Severe cases:

   • Intravenous (IV) phosphate: Given through a drip in hospital with heart monitoring
   • Usually takes 6-12 hours to give the dose slowly

3. Prevention (if you're at risk of refeeding syndrome):

   • Start food intake very slowly (low calories at first)
   • Take vitamin supplements (especially thiamine/vitamin B1) before starting to eat
   • Take phosphate, potassium, and magnesium tablets as a precaution
   • Have regular blood tests to check mineral levels

What Can I Do?

• Eat a balanced diet with phosphate-rich foods (dairy products, meat, fish, nuts, whole grains)
• Take prescribed supplements as directed by your doctor
• Avoid excessive antacid use (some antacids bind phosphate and reduce absorption)
• Attend follow-up appointments for blood test monitoring

Will I Recover?

Most people recover fully once phosphate levels are corrected. The key is:

• Early recognition and treatment
• Treating the underlying cause (e.g., improving nutrition, stopping harmful medications, treating kidney problems)
• Prevention in high-risk situations (such as careful refeeding in malnourished patients)

If you're at risk for refeeding syndrome (e.g., recovering from an eating disorder or severe malnutrition), your medical team will monitor you very closely and start nutrition slowly to prevent complications. With proper care, outcomes are excellent.

---

14. References

Primary Guidelines

1. NICE Clinical Guideline 32: Nutrition Support for Adults: Oral Nutrition Support, Enteral Tube Feeding and Parenteral Nutrition. National Institute for Health and Care Excellence. 2006 (updated 2017). Available at: https://www.nice.org.uk/guidance/cg32

Landmark Papers and Key Evidence

2. Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore). 2000;79(1):1-8. PMID: 10670405 DOI: 10.1097/00005792-200001000-00001

3. Geerse DA, Bindels AJ, Kuiper MA, et al. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care. 2010;14(4):R147. PMID: 20682037 DOI: 10.1186/cc9215

4. Mehanna HM, Moledina J, Travis J. Refeeding syndrome: what it is, and how to prevent and treat it. BMJ. 2008;336(7659):1495-1498. PMID: 18583681 DOI: 10.1136/bmj.a301

5. Liamis G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia: a review. QJM. 2010;103(7):449-459. PMID: 20231236 DOI: 10.1093/qjmed/hcq039

6. Zazzo JF, Troche G, Ruel P, Maintenant J. High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function. Intensive Care Med. 1995;21(10):826-831. PMID: 8557876 DOI: 10.1007/BF01712327

7. Charron T, Bernard F, Skrobik Y, et al. Intravenous phosphate in the intensive care unit: more aggressive repletion regimens for moderate and severe hypophosphatemia. Intensive Care Med. 2003;29(8):1273-1278. PMID: 12748851 DOI: 10.1007/s00134-003-1761-4

8. Rio A, Whelan K, Goff L, et al. Occurrence of refeeding syndrome in adults started on artificial nutrition support: prospective cohort study. BMJ Open. 2013;3(1):e002173. PMID: 23293244 DOI: 10.1136/bmjopen-2012-002173

9. National Collaborating Centre for Acute Care (UK). Nutrition Support for Adults: Oral Nutrition Support, Enteral Tube Feeding and Parenteral Nutrition. London: National Collaborating Centre for Acute Care (UK); 2006. (NICE Clinical Guidelines, No. 32.) PMID: 21309146

10. Wilson HK, Keuer SP, Lea AS, et al. Phosphate therapy in diabetic ketoacidosis. Arch Dis Child. 1982;57(1):36-40. PMID: 6799090 DOI: 10.1136/adc.57.1.36

11. Witteveen JE, van Thiel S, Romijn JA, Hamdy NA. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol. 2013;168(3):R45-R53. PMID: 23152439 DOI: 10.1530/EJE-12-0528

12. Crook MA, Hally V, Panteli JV. The importance of the refeeding syndrome. Nutrition. 2001;17(7-8):632-637. PMID: 11448586 DOI: 10.1016/s0899-9007(01)00542-1

13. Barak V, Schwartz A, Kalickman I, et al. Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines. Am J Med. 1998;104(1):40-47. PMID: 9528716 DOI: 10.1016/s0002-9343(97)00275-1

14. Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987-1998. PMID: 29791829 DOI: 10.1056/NEJMoa1714641

15. Foreman JW. Fanconi syndrome. Pediatr Clin North Am. 2019;66(1):159-167. PMID: 30454741 DOI: 10.1016/j.pcl.2018.09.002

Additional Key References

16. Amanzadeh J, Reilly RF Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol. 2006;2(3):136-148. PMID: 16932412 DOI: 10.1038/ncpneph0124

17. Gaasbeek A, Meinders AE. Hypophosphatemia: an update on its etiology and treatment. Am J Med. 2005;118(10):1094-1101. PMID: 16194637 DOI: 10.1016/j.amjmed.2005.02.014

18. Joint British Diabetes Societies Inpatient Care Group. The Management of Diabetic Ketoacidosis in Adults. 2021. Available at: https://abcd.care/joint-british-diabetes-societies-jbds-inpatient-care-group

---

Document Information

• Last Updated: 2026-01-06
• Topic ID: endo-hypophosphataemia
• Evidence Level: High
• Citation Count: 18
• Target Examinations: MRCP, FRACP, MRCPCH, ICU/Anaesthetics examinations
• Specialties: Endocrinology, Intensive Care Medicine, Nutrition, Nephrology